Written by: Ashrita Gollapalli (12th grade / Aldie, VA USA)
Editor: Noelle A. Koo (12th grade / Ashburn, VA USA)
Evodiamine is a quinazoline carboline alkaloid derived from a Chinese medicinal plant that has been previously used for the treatment for headaches, abdominal pain, postpartum hemorrhage, dysentery, and amenorrhea but recent studies have shown a promising future for the use of Evodiamine as an adjuvant for chemotherapy drugs(Jain et al., 2017). One of the main reasons Evodiamine has such promise is because similar to doxorubicin it also inhibits the TOP2 enzyme(Jain et al., 2017). Additionally, it has been found to cause cell cycle arrest at phase G2/M and induce cell death (Kim et al., 2018).
Recently, Evodiamine has begun to be used in combination with thyroid cancer cell lines. This has been seen in a study that did a proteomic analysis of Evodiamine induced cytotoxicity in thyroid cancer cells(Yu et al., 2018). Proteomics is a tool used to monitor protein expression changes during drug treatment(Yu et al., 2018). In their preliminary study, Evodiamine was shown to be toxic to thyroid cancer cells. The human thyroid cancer cell line was exposed to Evodiamine doses ranging from 0–5 μM, and it was found that there was a dose-dependent decrease in cell viability of the thyroid cancer cells(Yu et al., 2018). Furthermore, another study studying the effect of Evodiamine on thyroid cancer found similar results(Kim et al., 2018). This study found that Evodiamine increased the percentage of apoptotic cells in a dose dependent manner(Kim et al., 2018). In addition to this, with the use of Evodiamine it was found that the thyroid cancer cell growth was decreased as was the cell viability of the thyroid cancer cells(Kim et al., 2018).
These studies show that Evodiamine was effective in killing the thyroid cancer cells and reducing their cell viability, meaning it has a future as an effective treatment for thyroid cancer upon further trial. It can additionally be seen as an optimal treatment over other cancer drugs as it is a natural substitute for some of the more harmful cancer drugs.
Read more from the paper titled "Plant-based Therapies and Treatments for Thyroid Cancer" which can be found under the "Publications" tab.
Citations:
Kim, S.H., Kang, J.G., Kim, S.K., Ihm, S., Choi, .M.G., Lee, S.J.(2018). Evodiamine suppresses
survival,, proliferation, migration, and epithelial-mesenchymal transition of thyroid carcinoma cells. International Journal of Cancer Research and Treatment, 38(11), 6339-6352. http://doi.org/10.21873/anticanres.12992
Yu, H., Chou, H., Su, C., Lin, L., Lu, C., Chuanh, H., Tsai, Y., Liao, E., Wei, Y., Yang, Y., Lee,
Y., Chan, H. (2018). Proteomic analysis of evodiamine-induced cytotoxicity in thyroid cancer cells. Journal of Pharmaceutical and Biomedical Analysis, 160, 334-50. doi: 10.1016/j.jpba.2018.08.008
Comments